News

January 16, 2020

Neos Completes Dosing in Phase 1 Trial of Anti-Drooling Treatment NT0502 in Healthy Volunteers

News

Dosing of healthy volunteers has been completed in a Phase 1 clinical trial evaluating Neos Therapeutics‘ experimental therapy NT0502 for chronic sialorrhea (excessive drooling), a common problem in people with amyotrophic ... Read more

January 15, 2020January 15, 2020

Alexion to Initiate Phase 3 Trial of Ultomiris for Familiar, Sporadic ALS Patients

News

In the coming months, Alexion Pharmaceuticals will launch a pivotal Phase 3 clinical trial to test its complement system inhibitor Ultomiris (ravulizumab) in people with amyotrophic lateral sclerosis (ALS) whose ... Read more

January 14, 2020January 14, 2020

ALS Research Ambassador Collaboration Enabled More Patient-centered Design of REFINE-ALS Trial

News

Including ALS Research Ambassadors — a group of amyotrophic lateral sclerosis (ALS) patients and their caregivers — in discussions about future clinical trial planning and design facilitates changes in study protocol ... Read more

January 13, 2020January 13, 2020

AstroRx Increases Ability to Perform Daily Functions in ALS Patients, Trial Results Show

News

Amyotrophic lateral sclerosis (ALS) patients receiving the lowest dose of Kadimastem’s cell therapy candidate, AstroRx, experienced a significant reduction in disease progression in the three or four months after treatment, ... Read more

January 10, 2020January 10, 2020

Kadimastem Finishes Treating Second Group of ALS Patients with AstroRx in Phase 1/2a Trial

News

Kadimastem has finished treating its second group of participants in a Phase 1/2a clinical trial testing the safety and preliminary efficacy of AstroRx, an investigational stem cell therapy for amyotrophic ... Read more

January 9, 2020January 15, 2020

Mitochondrial ‘Suicide’ May Signal Start of Neurodegeneration in ALS, Mouse Study Suggests

News

A newly discovered self-destructive mechanism in mitochondria, the cells’ powerhouses, may be one of the first deficits leading to motor neuron degeneration associated with toxic TDP-43 clumps — a hallmark ... Read more

January 8, 2020January 8, 2020

Insurance Data May Predict ALS, Research Shows

News

A machine-learning model based on insurance information from amyotrophic lateral sclerosis (ALS) patients may be able to speed diagnosis of the disease in others, research suggests. The findings were ... Read more

January 7, 2020January 7, 2020

END ALS Association Founder Lights Up Room With Holiday Spirit to Raise Disease Awareness

News

The founder of the END ALS Association, Masahiro “Hiro” Fujita, can no longer move and can barely communicate because of amyotrophic lateral sclerosis (ALS). To help him enjoy the holidays ... Read more

January 6, 2020January 6, 2020

Top Scientist and Tattooed Patient Jointly Spur ALS Research in Sweden

News

Sweden, a nation of 10 million people, is becoming a major force in European ALS research through the recent opening of a clinical trials facility at Stockholm’s Karolinska Institute ... Read more

January 3, 2020January 3, 2020

BrainStorm Cell Therapeutics Wins 2020 ‘Buzz of BIO’ Award for Investigational Cellular Treatment

News

For its promising investigational therapeutic approach to neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS), BrainStorm Cell Therapeutics is the Buzz of BIO 2020 winner in the Public Therapeutic Biotech category. ... Read more

Pin It on Pinterest